Korro Bio Stock Climbs Before Holiday; Bigger Test Still to Come
Korro Bio Inc finished Friday at $11.61, gaining 3.66% for the session and up about 14% since May 15. The stock, listed on the Nasdaq, is now paused until Tuesday as U.S. equity markets are shut for Memorial Day on Monday. Korro is looking to steer the story back to its RNA-editing work after shaking up its alpha-1 antitrypsin deficiency, or AATD, program. This comes after the company tapped KRRO-111 as the AATD candidate on May 19, following a setback with its earlier drug, KRRO-110. KRRO-110 made the right protein in patients, but levels missed Korro’s target after the first dose.